The fungi Cordyceps militaris and Hirsutella sinensis are traditionally known for their immunomodulatory and anti-inflammatory properties, attracting growing interest in contemporary medicine as potential therapeutic agents for systemic sclerosis (SSc) and other diseases characterized by inflammatory and fibrotic processes. The aim of this master's thesis was to evaluate the anti-inflammatory and anti-fibrotic effects of various ethanol extracts of these fungi and cordycepin, presumed to be the primary bioactive compound, in vitro. We also investigated how different ethanol concentrations used during extract preparation influenced their biochemical composition and biological activities. Two cellular models were employed: the monocytic THP-1 cell line stimulated with lipopolysaccharide (LPS) and primary dermal fibroblasts (NHDF) stimulated with transforming growth factor-beta (TGF-β). The results confirmed the anti-inflammatory potential of fungal extracts, significantly reducing IL-6 and IL-1β expression in LPS-stimulated monocytes, with extracts prepared using higher ethanol concentrations demonstrating superior efficacy. Cordycepin alone did not exhibit anti-inflammatory activity in monocytes, likely due to rapid degradation by cellular adenosine deaminase (ADA); interestingly, fungal extracts naturally containing ADA inhibitors (such as pentostatin) effectively facilitated cordycepin's biological activity. Anti-fibrotic effects in fibroblasts were notably observed with H. sinensis extracts and the cordycepin-pentostatin combination, significantly decreasing the expression of key fibrotic markers (COL1A1, α-SMA, and fibronectin) at both mRNA and protein levels. Although C. militaris extracts did not consistently demonstrate anti-fibrotic effects across all repetitions, preliminary analyses suggest a promising potential warranting further validation. Dose-response evaluations allowed identification of effective yet non-toxic concentrations, a crucial step for future study design. Our research thus contributes significantly to understanding the complex anti-inflammatory and anti-fibrotic mechanisms of cordycepin and fungal extracts, highlighting the importance of concurrent ADA inhibition for cordycepin’s efficacy. Despite methodological constraints and the in vitro nature of this study, our findings provide a valuable foundation for future research and therapeutic development aimed at inflammatory-fibrotic diseases, such as systemic sclerosis.
|